User menu

Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: data from PREVAIL and AFFIRM trials.

Bibliographic reference Saad, F ; Ivanescu, C ; Phung, D ; Loriot, Y ; Abhyankar, S ; et. al. Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: data from PREVAIL and AFFIRM trials.. In: Prostate Cancer and Prostatic Diseases, Vol. 20, no.1, p. 110-116 (2017)
Permanent URL
  1. Butoescu V, Can J Urol, 21, 84 (2014)
  2. Hotte S. J., Saad F., Current management of castrate-resistant prostate cancer, 10.3747/co.v17i0.718
  3. Brown Janet E., Sim Sheryl, Evolving Role of Bone Biomarkers in Castration-Resistant Prostate Cancer, 10.1593/neo.10610
  4. Saad F., Gleason D. M., Murray R., Tchekmedyian S., Venner P., Lacombe L., Chin J. L., Vinholes J. J., Goas J. A., Zheng M., Long-Term Efficacy of Zoledronic Acid for the Prevention of Skeletal Complications in Patients With Metastatic Hormone-Refractory Prostate Cancer, 10.1093/jnci/djh141
  5. Beer Tomasz M., Armstrong Andrew J., Rathkopf Dana E., Loriot Yohann, Sternberg Cora N., Higano Celestia S., Iversen Peter, Bhattacharya Suman, Carles Joan, Chowdhury Simon, Davis Ian D., de Bono Johann S., Evans Christopher P., Fizazi Karim, Joshua Anthony M., Kim Choung-Soo, Kimura Go, Mainwaring Paul, Mansbach Harry, Miller Kurt, Noonberg Sarah B., Perabo Frank, Phung De, Saad Fred, Scher Howard I., Taplin Mary-Ellen, Venner Peter M., Tombal Bertrand, Enzalutamide in Metastatic Prostate Cancer before Chemotherapy, 10.1056/nejmoa1405095
  6. Scher Howard I., Fizazi Karim, Saad Fred, Taplin Mary-Ellen, Sternberg Cora N., Miller Kurt, de Wit Ronald, Mulders Peter, Chi Kim N., Shore Neal D., Armstrong Andrew J., Flaig Thomas W., Fléchon Aude, Mainwaring Paul, Fleming Mark, Hainsworth John D., Hirmand Mohammad, Selby Bryan, Seely Lynn, de Bono Johann S., Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy, 10.1056/nejmoa1207506
  7. Ayala-Ramirez Montserrat, Palmer J. Lynn, Hofmann Marie-Claude, de la Cruz Maxine, Moon Bryan S., Waguespack Steven G., Habra Mouhammed Amir, Jimenez Camilo, Bone Metastases and Skeletal-Related Events in Patients With Malignant Pheochromocytoma and Sympathetic Paraganglioma, 10.1210/jc.2012-4231
  8. Howard L E, De Hoedt A M, Aronson W J, Kane C J, Amling C L, Cooperberg M R, Terris M K, Divers C H, Valderrama A, Freedland S J, Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer?, 10.1038/pcan.2016.26
  9. Cathomas Richard, Bajory Zoltan, Bouzid Mounira, El Ghoneimy Ahmed, Gillessen Silke, Goncalves Frederico, Kacso Gabriel, Kramer Gero, Milecki Piotr, Pacik Dalibor, Tantawy Wahid, Lesniewski-Kmak Krzystof, Management of Bone Metastases in Patients with Castration-Resistant Prostate Cancer, 10.1159/000358258
  10. Loriot Yohann, Miller Kurt, Sternberg Cora N, Fizazi Karim, De Bono Johann S, Chowdhury Simon, Higano Celestia S, Noonberg Sarah, Holmstrom Stefan, Mansbach Harry, Perabo Frank G, Phung De, Ivanescu Cristina, Skaltsa Konstantina, Beer Tomasz M, Tombal Bertrand, Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial, 10.1016/s1470-2045(15)70113-0
  11. Autio Karen A., Scher Howard I., Morris Michael J., Therapeutic Strategies for Bone Metastases and Their Clinical Sequelae in Prostate Cancer, 10.1007/s11864-012-0190-8
  12. Moul Judd W., Dawson Nancy, Quality of Life Associated with Treatment of Castration-Resistant Prostate Cancer: A Review of the Literature, 10.3109/07357907.2011.629381
  13. Fizazi Karim, Scher Howard I, Miller Kurt, Basch Ethan, Sternberg Cora N, Cella David, Forer David, Hirmand Mohammad, de Bono Johann S, Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial, 10.1016/s1470-2045(14)70303-1
  14. Cella D., Ivanescu C., Holmstrom S., Bui C. N., Spalding J., Fizazi K., Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial, 10.1093/annonc/mdu510
  15. Esper Peg, Mo Fei, Chodak Gerald, Sinner Michael, Cella David, Pienta Kenneth J., Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-prostate instrument, 10.1016/s0090-4295(97)00459-7
  16. Cella David, Nichol Michael B., Eton David, Nelson Joel B., Mulani Parvez, Estimating Clinically Meaningful Changes for the Functional Assessment of Cancer Therapy—Prostate: Results from a Clinical Trial of Patients with Metastatic Hormone-Refractory Prostate Cancer, 10.1111/j.1524-4733.2008.00409.x
  17. Victorson DE, Psychooncology, 20, 977 (2011)
  18. Rabin Rosalind, Charro Frank de, EQ-SD: a measure of health status from the EuroQol Group, 10.3109/07853890109002087
  19. Samsa Greg, Edelman David, Rothman Margaret L., Williams G Rhys, Lipscomb Joseph, Matchar David, Determining Clinically Important Differences in Health Status Measures : A General Approach with Illustration to the Health Utilities Index Mark II, 10.2165/00019053-199915020-00003
  20. Cella David, Hahn Elizabeth A., Dineen Kelly, 10.1023/a:1015276414526
  21. Yost Kathleen J., Eton David T., Combining Distribution- and Anchor-Based Approaches to Determine Minimally Important Differences : The FACIT Experience, 10.1177/0163278705275340
  22. Pickard A Simon, Neary Maureen P, Cella David, Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer, 10.1186/1477-7525-5-70
  23. Flounders Jo Ann, Ott Barbara B., Oncology Emergency Modules: Spinal Cord Compression, 10.1188/03.onf.e17-e23
  24. Abrahm Janet L., Banffy Michael B., Harris Mitchel B., Spinal Cord Compression in Patients With Advanced Metastatic Cancer : “All I Care About Is Walking and Living My Life”, 10.1001/jama.299.8.937
  25. Sutcliffe P, Health Technol Assess, 17, 1 (2013)
  26. Weinfurt K. P., Li Y., Castel L. D., Saad F., Timbie J. W., Glendenning G. A., Schulman K. A., The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer, 10.1093/annonc/mdi122
  27. Piccioli Andrea, Rossi Barbara, Scaramuzzo Laura, Spinelli Maria Silvia, Yang Zuozhang, Maccauro Giulio, Intramedullary nailing for treatment of pathologic femoral fractures due to metastases, 10.1016/j.injury.2013.09.025
  28. Saad Fred, Lipton Allan, Cook Richard, Chen Yin-Miao, Smith Matthew, Coleman Robert, Pathologic fractures correlate with reduced survival in patients with malignant bone disease, 10.1002/cncr.22991
  29. Sieber P, Rev Urol, 16, 10 (2014)
  30. Merseburger Axel S., Haas Gabriel P., von Klot Christoph-A., An update on enzalutamide in the treatment of prostate cancer, 10.1177/1756287214555336